Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T71377
|
||||
Former ID |
TTDR00012
|
||||
Target Name |
Interleukin 3 receptor
|
||||
Gene Name |
IL3RA
|
||||
Synonyms |
CD123 antigen; IL-3R-alpha; IL3RA
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Acute lymphoblastic leukemia; Acute myeloid lymphoma [ICD9:204.0, 556; ICD10: C91.0, C92.0] | ||||
Leukemia [ICD9: 208.9; ICD10: C90-C95] | |||||
Osteoporosis [ICD9: 733.0, V07.4; ICD10: M80-M81, Z79.890] | |||||
Function |
This is a receptor for interleukin-3.
|
||||
BioChemical Class |
Cytokine receptor
|
||||
UniProt ID | |||||
Sequence |
MVLLWLTLLLIALPCLLQTKEDPNPPITNLRMKAKAQQLTWDLNRNVTDIECVKDADYSM
PAVNNSYCQFGAISLCEVTNYTVRVANPPFSTWILFPENSGKPWAGAENLTCWIHDVDFL SCSWAVGPGAPADVQYDLYLNVANRRQQYECLHYKTDAQGTRIGCRFDDISRLSSGSQSS HILVRGRSAAFGIPCTDKFVVFSQIEILTPPNMTAKCNKTHSFMHWKMRSHFNRKFRYEL QIQKRMQPVITEQVRDRTSFQLLNPGTYTVQIRARERVYEFLSAWSTPQRFECDQEEGAN TRAWRTSLLIALGTLLALVCVFVICRRYLVMQRLFPRIPHMKDPIGDSFQNDKLVVWEAG KAGLEECLVTEVQVVQKT |
||||
Drugs and Mode of Action | |||||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
PI3K-Akt signaling pathway | |||||
Apoptosis | |||||
Jak-STAT signaling pathway | |||||
Hematopoietic cell lineage | |||||
NetPath Pathway | IL5 Signaling Pathway | ||||
IL3 Signaling Pathway | |||||
Pathway Interaction Database | IL3-mediated signaling events | ||||
Reactome | GPVI-mediated activation cascade | ||||
gamma signalling through PI3Kgamma | |||||
Interleukin-3, 5 and GM-CSF signaling | |||||
RAF/MAP kinase cascade | |||||
Interleukin receptor SHC signaling | |||||
WikiPathways | IL-3 Signaling Pathway | ||||
Interleukin-2 signaling | |||||
Interleukin-3, 5 and GM-CSF signaling | |||||
References | |||||
Ref 544458 | A Phase I trial of MGD006 in patients with relapsed acute myeloid leukemia (AML). J Immunother Cancer. 2014; 2(Suppl 3): P87. | ||||
Ref 546034 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005988) | ||||
Ref 532602 | Monoclonal antibody targeting of IL-3 receptor alpha with CSL362 effectively depletes CML progenitor and stem cells. Blood. 2014 Feb 20;123(8):1218-28. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.